$7.24
Verrica Pharmaceuticals is a biotechnology business based in the US. Verrica Pharmaceuticals shares (VRCA) are listed on the NASDAQ and all prices are listed in US Dollars. Verrica Pharmaceuticals employs 100 staff and has a trailing 12-month revenue of around $8.9 million.
Our top picks for where to buy Verrica Pharmaceuticals stock
How to buy Verrica Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VRCA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Verrica Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Verrica Pharmaceuticals stock price (NASDAQ: VRCA)
Use our graph to track the performance of VRCA stocks over time.Verrica Pharmaceuticals shares at a glance
Latest market close | $7.25 |
---|---|
52-week range | $2.86 - $11.41 |
50-day moving average | $8.19 |
200-day moving average | $5.93 |
Wall St. target price | $15.50 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.77 |
Is it a good time to buy Verrica Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Verrica Pharmaceuticals price performance over time
Historical closes compared with the close of $7.25 from 2024-07-25
1 week (2024-07-19) | 2.98% |
---|---|
1 month (2024-06-26) | 2.84% |
3 months (2024-04-26) | 5.53% |
6 months (2024-01-26) | 25.22% |
1 year (2023-07-26) | 36.66% |
---|---|
2 years (2022-07-26) | 123.08% |
3 years (2021-07-26) | 10.82 |
5 years (2019-07-26) | 10.91 |
Verrica Pharmaceuticals financials
Revenue TTM | $8.9 million |
---|---|
Gross profit TTM | $8.3 million |
Return on assets TTM | -69.22% |
Return on equity TTM | -243.35% |
Profit margin | 0% |
Book value | $0.04 |
Market Capitalization | $298.6 million |
TTM: trailing 12 months
Verrica Pharmaceuticals share dividends
We're not expecting Verrica Pharmaceuticals to pay a dividend over the next 12 months.
Verrica Pharmaceuticals share price volatility
Over the last 12 months, Verrica Pharmaceuticals's shares have ranged in value from as little as $2.86 up to $11.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verrica Pharmaceuticals's is 1.562. This would suggest that Verrica Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Verrica Pharmaceuticals overview
Verrica Pharmaceuticals Inc. , a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co. , Ltd.
Frequently asked questions
What percentage of Verrica Pharmaceuticals is owned by insiders or institutions?Currently 34.972% of Verrica Pharmaceuticals shares are held by insiders and 42.549% by institutions. How many people work for Verrica Pharmaceuticals?
Latest data suggests 100 work at Verrica Pharmaceuticals. When does the fiscal year end for Verrica Pharmaceuticals?
Verrica Pharmaceuticals's fiscal year ends in December. Where is Verrica Pharmaceuticals based?
Verrica Pharmaceuticals's address is: 44 West Gay Street, West Chester, PA, United States, 19380 What is Verrica Pharmaceuticals's ISIN number?
Verrica Pharmaceuticals's international securities identification number is: US92511W1080 What is Verrica Pharmaceuticals's CUSIP number?
Verrica Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92511W108
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question